Eleven Biotherapeutics Company Profile (NASDAQ:EBIO)

About Eleven Biotherapeutics (NASDAQ:EBIO)

Eleven Biotherapeutics logoEleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company's product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis. The Company's therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to design and engineer proteins to modulate the effects of cytokines. The Company is developing EBI-031 as an intravitreal injection for DME and uveitis. In addition to EBI-031, the Company has another product candidate in early preclinical development, which is designed to block vascular endothelial growth factor (VEGF).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:EBIO
  • CUSIP: N/A
  • Web: www.elevenbio.com
Capitalization:
  • Market Cap: $22.78 million
  • Outstanding Shares: 15,393,000
Average Prices:
  • 50 Day Moving Avg: $1.77
  • 200 Day Moving Avg: $2.05
  • 52 Week Range: $1.12 - $5.97
P/E:
  • Trailing P/E Ratio: 9.80
  • Foreward P/E Ratio: -0.80
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $30.18 million
  • Price / Sales: 0.75
  • Book Value: $1.33 per share
  • Price / Book: 1.11
Profitability:
  • EBIDTA: $8.26 million
  • Net Margins: -16.51%
  • Return on Equity: -25.00%
  • Return on Assets: -14.02%
Debt:
  • Current Ratio: 5.08%
  • Quick Ratio: 5.08%
Misc:
  • Average Volume: 443,181 shs.
  • Beta: 3.69
  • Short Ratio: 6.68
 

Frequently Asked Questions for Eleven Biotherapeutics (NASDAQ:EBIO)

What is Eleven Biotherapeutics' stock symbol?

Eleven Biotherapeutics trades on the NASDAQ under the ticker symbol "EBIO."

How were Eleven Biotherapeutics' earnings last quarter?

Eleven Biotherapeutics Inc (NASDAQ:EBIO) announced its quarterly earnings results on Thursday, May, 4th. The company reported ($0.25) earnings per share (EPS) for the quarter. The business had revenue of $0.43 million for the quarter. Eleven Biotherapeutics had a negative net margin of 16.51% and a negative return on equity of 25.00%. View Eleven Biotherapeutics' Earnings History.

Are investors shorting Eleven Biotherapeutics?

Eleven Biotherapeutics saw a decrease in short interest in April. As of April 13th, there was short interest totalling 1,670,895 shares, a decrease of 11.9% from the March 31st total of 1,897,128 shares. Based on an average daily trading volume, of 638,058 shares, the days-to-cover ratio is currently 2.6 days.

Who are some of Eleven Biotherapeutics' key competitors?

Who owns Eleven Biotherapeutics stock?

Eleven Biotherapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Flagship Pioneering Inc. (8.60%), FLAGSHIP VENTURES FUND 2007, L.P. Total Shares: 1,066,451 (4.30%), Vanguard Group Inc. (1.14%) and Geode Capital Management LLC (0.31%). Company insiders that own Eleven Biotherapeutics stock include Abbie Celniker, Boxer Capital, Llc, Eric Steven Furfine, John J Mccabe, Karen L Tubridy, Ventures Fund 2007 L Flagship and Ventures Fund Iv LP Flagship. View Institutional Ownership Trends for Eleven Biotherapeutics.

Who bought Eleven Biotherapeutics stock? Who is buying Eleven Biotherapeutics stock?

Eleven Biotherapeutics' stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and Geode Capital Management LLC. View Insider Buying and Selling for Eleven Biotherapeutics.

How do I buy Eleven Biotherapeutics stock?

Shares of Eleven Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Eleven Biotherapeutics stock cost?

One share of Eleven Biotherapeutics stock can currently be purchased for approximately $1.48.

Analyst Ratings

Consensus Ratings for Eleven Biotherapeutics (NASDAQ:EBIO) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Eleven Biotherapeutics (NASDAQ:EBIO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
1/19/2016Citigroup IncDowngradeBuy -> NeutralN/AView Rating Details
1/18/2016Leerink SwannDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for Eleven Biotherapeutics (NASDAQ:EBIO)
Earnings by Quarter for Eleven Biotherapeutics (NASDAQ:EBIO)
Earnings History by Quarter for Eleven Biotherapeutics (NASDAQ:EBIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.25)$0.43 millionViewListenView Earnings Details
3/24/2017Q4 2016($0.12)($0.20)$0.83 millionViewN/AView Earnings Details
11/14/2016Q3($0.17)$0.91$28.70 millionViewListenView Earnings Details
8/12/2016Q2($0.33)$0.28 millionViewN/AView Earnings Details
3/24/2016Q4($0.32)($0.53)$0.57 millionViewN/AView Earnings Details
11/4/2015Q315($0.44)($0.50)$0.10 million$0.07 millionViewListenView Earnings Details
8/13/2015Q215($0.43)($0.36)$0.20 million$0.11 millionViewListenView Earnings Details
4/30/2015Q115($0.57)($0.36)$0.20 million$0.24 millionViewListenView Earnings Details
3/4/2015Q414($0.33)($0.49)$0.80 million$0.38 millionViewListenView Earnings Details
11/13/2014Q314($0.45)($0.66)$0.70 million$0.54 millionViewN/AView Earnings Details
8/13/2014Q2 2014($0.47)($0.51)$0.10 million$0.76 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Eleven Biotherapeutics (NASDAQ:EBIO)
Current Year EPS Consensus Estimate: $-1.75 EPS
Next Year EPS Consensus Estimate: $-1.85 EPS

Dividends

Dividend History for Eleven Biotherapeutics (NASDAQ:EBIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Eleven Biotherapeutics (NASDAQ:EBIO)
Insider Ownership Percentage: 28.70%
Institutional Ownership Percentage: 24.75%
Insider Trades by Quarter for Eleven Biotherapeutics (NASDAQ:EBIO)
Institutional Ownership by Quarter for Eleven Biotherapeutics (NASDAQ:EBIO)
Insider Trades by Quarter for Eleven Biotherapeutics (NASDAQ:EBIO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/28/2016Abbie CelnikerDirectorSell10,031$3.00$30,093.00View SEC Filing  
9/23/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell443,422$3.16$1,401,213.52View SEC Filing  
9/21/2016Ventures Fund Iv L.P FlagshipMajor ShareholderSell322,723$3.75$1,210,211.25View SEC Filing  
9/20/2016Ventures Fund Iv L.P FlagshipMajor ShareholderSell53,917$3.39$182,778.63View SEC Filing  
9/19/2016Ventures Fund Iv L.P FlagshipMajor ShareholderSell9,700$3.31$32,107.00View SEC Filing  
9/15/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell46,692$4.18$195,172.56View SEC Filing  
9/7/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell129,497$4.54$587,916.38View SEC Filing  
8/15/2016John J MccabeCFOSell1,170$4.80$5,616.00View SEC Filing  
6/27/2016Abbie CelnikerCEOSell10,029$2.08$20,860.32View SEC Filing  
6/27/2016Karen L TubridyInsiderSell4,372$2.08$9,093.76View SEC Filing  
6/13/2016Boxer Capital, LlcMajor ShareholderSell1,042,000$2.74$2,855,080.00View SEC Filing  
2/16/2016John J MccabeSVPSell1,501$0.27$405.27View SEC Filing  
12/28/2015Abbie CelnikerCEOSell10,155$2.85$28,941.75View SEC Filing  
12/28/2015Eric Steven FurfineInsiderSell4,652$2.85$13,258.20View SEC Filing  
5/8/2015Jafco Super V3 Investment LimiMajor ShareholderSell33,400$13.23$441,882.00View SEC Filing  
2/2/2015Jafco Super V3 Investment LimiMajor ShareholderSell17,900$11.62$207,998.00View SEC Filing  
1/30/2015Jafco Super V3 Investment LimiMajor ShareholderSell120,000$11.62$1,394,400.00View SEC Filing  
1/26/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,300$11.85$74,655.00View SEC Filing  
1/22/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,300$11.82$74,466.00View SEC Filing  
1/16/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,100$12.07$73,627.00View SEC Filing  
8/26/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,000$11.54$23,080.00View SEC Filing  
8/20/2014Jafco Super V3 Investment LimiMajor ShareholderSell1,165$11.54$13,444.10View SEC Filing  
8/18/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,600$11.81$30,706.00View SEC Filing  
8/14/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,000$11.75$23,500.00View SEC Filing  
2/11/2014Jafco Super V3 Investment LimiMajor ShareholderBuy219,790$10.00$2,197,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Eleven Biotherapeutics (NASDAQ:EBIO)
Latest Headlines for Eleven Biotherapeutics (NASDAQ:EBIO)
Source:
DateHeadline
businesswire.com logoEleven Biotherapeutics Continues Expansion of Clinical ... - Business Wire (press release)
www.businesswire.com - May 17 at 4:54 PM
finance.yahoo.com logoEleven Biotherapeutics Continues Expansion of Clinical Development Team with Appointment of David Brooks, M.D., Ph.D., to Senior Vice President, Clinical Development
finance.yahoo.com - May 17 at 11:06 AM
americanbankingnews.com logoZacks Investment Research Upgrades Eleven Biotherapeutics Inc (EBIO) to "Hold"
www.americanbankingnews.com - May 16 at 6:26 PM
finance.yahoo.com logoETFs with exposure to Eleven Biotherapeutics, Inc. : May 15, 2017
finance.yahoo.com - May 15 at 4:39 PM
americanbankingnews.com logoShort Interest in Eleven Biotherapeutics Inc (EBIO) Drops By 11.9%
www.americanbankingnews.com - May 10 at 7:18 AM
finance.yahoo.com logoEleven Biotherapeutics, Inc. :EBIO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 8, 2017
finance.yahoo.com - May 8 at 4:46 PM
americanbankingnews.com logoEleven Biotherapeutics Inc (EBIO) Announces Earnings Results
www.americanbankingnews.com - May 8 at 3:36 PM
americanbankingnews.com logoEleven Biotherapeutics Inc (EBIO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 5 at 7:38 PM
americanbankingnews.com logoEleven Biotherapeutics (EBIO) Getting Somewhat Positive Media Coverage, Study Shows
www.americanbankingnews.com - May 4 at 5:08 PM
finance.yahoo.com logoEleven Biotherapeutics Reports First Quarter 2017 Financial Results - Yahoo Finance
finance.yahoo.com - May 4 at 5:01 PM
finance.yahoo.com logoInvestor Network: Eleven Biotherapeutics, Inc. to Host Earnings Call
finance.yahoo.com - May 4 at 9:47 AM
finance.yahoo.com logoEleven Biotherapeutics Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 4 at 9:47 AM
finance.yahoo.com logoETFs with exposure to Eleven Biotherapeutics, Inc. : May 3, 2017
finance.yahoo.com - May 3 at 4:45 PM
finance.yahoo.com logoEleven Biotherapeutics to Report First Quarter 2017 Financial Results on Thursday, May 4, 2017 - Yahoo Finance
finance.yahoo.com - April 28 at 11:02 PM
finance.yahoo.com logoEleven Biotherapeutics to Report First Quarter 2017 Financial Results on Thursday, May 4, 2017
finance.yahoo.com - April 28 at 5:58 PM
americanbankingnews.com logoSomewhat Critical News Coverage Very Unlikely to Affect Eleven Biotherapeutics (EBIO) Stock Price
www.americanbankingnews.com - April 27 at 5:08 PM
americanbankingnews.com logoEleven Biotherapeutics (EBIO) Given Daily News Sentiment Score of 0.31
www.americanbankingnews.com - April 24 at 5:45 PM
finance.yahoo.com logoETFs with exposure to Eleven Biotherapeutics, Inc. : April 21, 2017
finance.yahoo.com - April 21 at 4:55 PM
americanbankingnews.com logoEleven Biotherapeutics (EBIO) Getting Positive News Coverage, Analysis Finds
www.americanbankingnews.com - April 19 at 10:07 AM
americanbankingnews.com logoEleven Biotherapeutics (EBIO) Receiving Critical Press Coverage, Analysis Finds
www.americanbankingnews.com - April 14 at 7:48 AM
streetinsider.com logoEleven Biotherapeutics (EBIO) Presents New Preclinical Data With ... - StreetInsider.com
www.streetinsider.com - April 4 at 7:07 AM
biz.yahoo.com logoELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - April 4 at 7:07 AM
finance.yahoo.com logoEleven Biotherapeutics Presents New Preclinical Data at AACR Supporting the Potential of the Company’s Locally- and Systematically-Administered Drug Candidates
finance.yahoo.com - April 2 at 4:47 PM
finance.yahoo.com logoELEVEN BIOTHERAPEUTICS, INC. Financials
finance.yahoo.com - March 30 at 5:18 PM
streetinsider.com logoEleven Biotherapeutics (EBIO) to Present New Preclinical Data at AACR
www.streetinsider.com - March 28 at 12:04 PM
finance.yahoo.com logoEleven Biotherapeutics to Present New Preclinical Data at the American Association for Cancer Research Annual Meeting 2017
finance.yahoo.com - March 27 at 12:05 PM
finance.yahoo.com logo7:02 am Eleven Biotherapeutics will present preclinical data 'supporting the ongoing development of its locally- and systemically-administered drug candidates' at the AACR Annual Meeting 2017, on April 2
finance.yahoo.com - March 27 at 12:05 PM
baystreet.ca logoEleven Biotherapeutics (EBIO) Gains Ahead of Q4 Earnings
www.baystreet.ca - March 26 at 4:36 PM
finance.yahoo.com logoEleven Biotherapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
finance.yahoo.com - March 24 at 9:40 AM
biz.yahoo.com logoQ4 2016 Eleven Biotherapeutics Inc Earnings Release - Time Not Supplied
biz.yahoo.com - March 24 at 9:40 AM
biz.yahoo.com logoELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
biz.yahoo.com - March 24 at 9:40 AM
americanbankingnews.com logoEleven Biotherapeutics Inc (EBIO) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 24 at 9:17 AM
seekingalpha.com logoEleven Biotherapeutics (EBIO) Presents At Oppenheimer 27th Annual Healthcare Conference
seekingalpha.com - March 22 at 4:59 PM
finance.yahoo.com logoEleven Biotherapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on Friday, March 24, 2017
finance.yahoo.com - March 22 at 4:59 PM
americanbankingnews.com logoEleven Biotherapeutics Inc (EBIO) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - March 21 at 7:34 AM
finance.yahoo.com logoEleven Biotherapeutics to Present at Oppenheimer's 27th Annual Healthcare Conference
finance.yahoo.com - March 20 at 7:44 PM
biz.yahoo.com logoELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - March 7 at 11:55 AM
finance.yahoo.com logoEleven Biotherapeutics to Present at Upcoming Investor Conferences in March
finance.yahoo.com - March 1 at 12:51 PM
seekingalpha.com logoEleven Biotherapeutics (EBIO) Presents At 19th Annual BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 16 at 8:41 PM
seekingalpha.com logoEleven Biotherapeutics (EBIO) Presents At 19th Annual BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 16 at 8:41 PM
prnewswire.com logoHow These Biotech Stocks are Faring? -- Agenus, Tokai Pharma, Eleven Biotherapeutics, and Rexahn Pharma - PR Newswire (press release)
www.prnewswire.com - February 14 at 5:46 PM
finance.yahoo.com logoEleven Biotherapeutics to Present at the 2017 BIO CEO & Investor Conference
finance.yahoo.com - February 7 at 6:01 PM
biz.yahoo.com logoELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events
biz.yahoo.com - January 6 at 5:23 PM

Social

Chart

Eleven Biotherapeutics (EBIO) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff